Catheter ablation for atrial fibrillation (AF) is a cornerstone of rhythm control.
Guideline recommends catheter ablation as a Class I indication for patients with symptomatic AF (paroxysmal or persistent) who have failed, are intolerant to, or have contraindications to antiarrhythmic drug (AAD) therapy and in whom continued rhythm control is desired.
In selected patients—particularly those who are younger, have few comorbidities, and present with symptomatic paroxysmal AF—catheter ablation is also recommended as a first-line therapy to improve symptoms and reduce progression to persistent AF.
Large randomized controlled trials (RCTs) such as CABANA, STOP-AF, and EARLY-AF, which demonstrate superior efficacy of ablation over AADs in reducing recurrent symptomatic AF and improving quality of life, with procedural complication rates generally in the 2–5% range.
For patients with persistent AF, ablation is indicated when symptoms persist despite medical therapy, with the greatest benefit observed in those with relatively recent onset.
Catheter ablation is also recommended for symptomatic or clinically significant atrial flutter, and in patients with heart failure with reduced ejection fraction (HFrEF), ablation may be considered to reduce mortality and hospitalizations, though the evidence is less robust and guidelines recommend similar indications as in patients without heart failure.
Patient selection should incorporate age, comorbidities, left atrial size, duration of AF, and patient preferences, with the primary goal being symptom improvement and quality of life enhancement.
Catheter ablation for AF is performed with the primary goal of durable pulmonary vein isolation (PVI), as the pulmonary veins are the predominant source of AF triggers.
The three main ablation modalities are radiofrequency ablation (RFA), cryoballoon ablation (CBA), and pulsed field ablation (PFA), each with distinct mechanisms, efficacy, and safety profiles.
Radiofrequency ablation utilizes point-by-point thermal energy to create transmural lesions around the pulmonary veins.
The introduction of contact force-sensing catheters has improved quality and reduced complications.
RFA is the most established technique, with freedom from atrial arrhythmia at one year ranging from 65–80% in paroxysmal AF and lower rates in persistent AF.
Cryoballoon ablation, a single-shot technique using cryothermal energy, is less operator-dependent and associated with shorter procedure times.
Multiple meta-analyses and RCTs have shown that CBA is non-inferior to RFA in terms of efficacy and safety for both paroxysmal and persistent AF, with similar rates of freedom from arrhythmia at one year.
The main ablation modalities—radiofrequency, cryoballoon, and pulsed field ablation—offer equivalent efficacy and overall safety, with pulsed field ablation emerging as a promising technology with potential safety advantages.
CBA is associated with a higher incidence of phrenic nerve palsy (0.2–0.4%), which is usually transient but can rarely be persistent.
Both RFA and CBA are endorsed as first-line ablation options
by the American College of Cardiology and associated societies.[1]
Pulsed field ablation is a nonthermal technique that uses high-voltage, microsecond-scale electrical fields to induce irreversible electroporation, selectively ablating myocardial tissue while sparing adjacent structures such as the esophagus and phrenic nerve.
Large RCTs: ADVENT and SINGLE SHOT CHAMPION trials, have demonstrated that PFA is non-inferior to conventional thermal ablation (RFA or CBA) in terms of efficacy for paroxysmal AF, with similar or lower rates of freedom from arrhythmia at one year and a favorable safety profile.
PFA is associated with shorter procedure and left atrial dwell times compared to RFA and CBA, and to date, no cases of atrioesophageal fistula have been reported in large series.
PFA as an emerging technology with the potential to improve safety and efficiency, though long-term data and broader adoption are still evolving.
The choice of ablation technique should be individualized based on patient anatomy, operator experience, and institutional resources, with all modalities aiming for durable PVI as the cornerstone of AF ablation.
Catheter ablation for AF offers high success rates for freedom from arrhythmia, particularly in paroxysmal AF.
After a single ablation, 1-year freedom from AF is 66–77% for paroxysmal AF and 42–54% for persistent AF, with long-term (5-year) rates of 48–68% and 27–47%, respectively.
Repeat ablation improves long-term success rates, with freedom from AF at 5, 10, and 15 years reaching 80%, 73%, and 63% for paroxysmal AF, and 60%, 50%, and 43% for persistent AF.
The highest risk of recurrence is within the first two years post-ablation, after which the annual recurrence rate stabilizes at approximately 2% per year for all AF types.
Predictors of long-term success include younger age, smaller left atrial size, shorter AF duration, male sex, paroxysmal AF, lower CHA₂DS₂-VASc score, fewer failed drugs, and more recent ablation technology.
Ablation is superior to AADs for maintaining sinus rhythm and reducing arrhythmia recurrence.
The CABANA trial found a 50% reduction in recurrent AF with ablation compared to drug therapy
Meta-analyses report a 38% higher rate of freedom from recurrent arrhythmia with ablation (53% vs 32.3%) with a number needed to treat of 5 to prevent one arrhythmia recurrence.
The superiority of ablation is most pronounced in paroxysmal AF, but patients with persistent AF and low structural heart disease burden also derive substantial benefit.
Symptom improvement and quality of life (QOL) are major drivers for ablation referral.
The CABANA trial demonstrated significant improvements in QOL with ablation compared to drug therapy, as measured by quality of life scores.
The CAPTAF trial corroborated these findings, showing that ablation patients achieved QOL scores comparable to the general population at 12 months.
Psychological well-being also improved more with ablation, with lower Hospital Anxiety and Depression Scale (HADS) scores and greater reductions in AF symptom severity.
Catheter ablation for AF carries a risk of both short-term and long-term complications.
The overall complication rate is approximately 4–5%, with most complications being vascular in nature.
Severe complications occur in about 2–2.5% of cases, and the procedure-related mortality rate is low, generally less than 0.1%.
The most common short-term complications are vascular access complications (1–7%), cardiac tamponade (0.4–1.5%), and stroke or transient ischemic attack (0.1–1.0%).
Phrenic nerve injury occurs in 0.2–0.4% of cases, more commonly with CBA than RFA.
Pulmonary vein stenosis is a rare late complication (0.1–0.8%), and atrioesophageal fistula, though exceedingly rare (0.02–0.2%), is often fatal if not promptly recognized and treated.
The risk of complications is higher in lower-volume centers, among operators with less experience, and in patients with advanced age, frailty, or comorbidities.
Elderly patients (≥75 years) have similar efficacy rates to younger patients (59–65% freedom from AF at 2–3 years) but experience higher rates of major complications (risk ratio 1.3–1.6), particularly stroke and vascular events.
Frailty, independent of age, is a strong predictor of adverse outcomes, including in-hospital mortality and major adverse cardiac and cerebrovascular events.
Patients with significant comorbidities, such as heart failure, obesity, sleep apnea, and advanced atrial remodeling, have lower success rates and higher complication rates, underscoring the importance of aggressive risk factor management.
Disparities in access to and outcomes of AF ablation based on sex, race/ethnicity, and socioeconomic status: Women, Black and Hispanic patients, and those with lower SES are less likely to be referred for and to receive ablation, often after longer delays and more failed therapies.
These disparities persist even in insured populations and after adjustment for comorbidities and healthcare utilization.
When ablation is performed, procedural outcomes are generally comparable across groups, though women may have slightly lower single-procedure success rates, which are mitigated with repeat procedures.
Long-term freedom from AF after ablation is substantial but not absolute.
After a single ablation, freedom from AF at 5, 10, and 15 years is 68%, 56%, and 48% for paroxysmal AF, and 47%, 36%, and 27% for persistent AF.
With multiple procedures, these rates improve to 80%, 73%, and 63% for paroxysmal AF, and 60%, 50%, and 43% for persistent AF.
The need for repeat ablation is common, particularly in the first two years, but long-term recurrence rates stabilize at approximately 2% per year.
Catheter ablation is associated with a reduction in long-term stroke (relative risk 0.63) and all-cause mortality (relative risk 0.73) compared to medical therapy.
The main clinical benefit remains symptom reduction and improved quality of life, with a low incidence of major adverse events in the long term.
Catheter ablation is associated with higher initial costs compared to medical therapy, but provides intermediate economic value and is cost-effective over time.
Ablation leads to sustained decreases in hospitalizations, emergency department visits, and medication burden, with the greatest benefit observed in patients with symptomatic paroxysmal AF and those treated earlier in the disease course.
Post-ablation follow-up is essential to monitor for arrhythmia recurrence, optimize anticoagulation management, and address modifiable risk factors.
A structured follow-up schedule, with visits at 3, 6, and 12 months post-ablation, including a 12-lead ECG at each visit and 24-hour Holter monitoring every 6 months is recommended.
Continuous or frequent ECG monitoring is particularly important for patients considering anticoagulation discontinuation, given the high prevalence of asymptomatic AF recurrence.
Oral anticoagulation should be continued for at least 3 months post-ablation, with longer-term therapy dictated by the CHA₂DS₂-VASc score.
Patients with a score ≥2 (men) or ≥3 (women) should continue anticoagulation indefinitely, regardless of arrhythmia recurrence status.
Patients with atrial fibrillation who have a low to moderate risk of stroke with a CHA₂DS₂-VASc score of two or less and undergo successful catheter ablation and monitoring for recurrent atrial fibrillation have a low enough risk of stroke that continued use of oral anticoagulants may not be justified, particularly given associated risks of bleeding.
Among patients who have had a successful catheter ablation for AF at least one year earlier and had risk factors for stroke, treatment with rivaroxaban, did not result in a significant lower incidence of composite stroke, systemic embolism, or new covert embolic stroke, than treatment with aspirin (OCEAN investigators).
Direct oral anticoagulants (DOACs) are preferred over warfarin for most patients, with apixaban and rivaroxaban being options for those with renal impairment.
Risk factor modification is a cornerstone of post-ablation management: weight loss, regular exercise, smoking cessation, minimization of alcohol intake, and optimal blood pressure and glycemic control are all recommended to reduce AF recurrence and improve outcomes.
Catheter ablation for atrial fibrillation is a guideline-endorsed, highly effective therapy for symptomatic patients who have failed or are intolerant to antiarrhythmic drugs, and is increasingly considered as first-line therapy in selected younger patients with paroxysmal AF.
Complication rates are low but not negligible, with higher risks in elderly, frail, and comorbid patients.